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ABSTRACT The United States has been a leader in biomedical science for decades, in large 
part because of the strategy used by the National Institutes of Health (NIH) to invest its bud-
getary portfolio. They identified talented young scientists from each generation and gave 
them the resources they needed to initiate and maintain strong research programs. However, 
recently this investment has become less diversified, with a larger fraction of grant dollars in 
the hands of a smaller fraction of researchers. This threatens the future of our field, as many 
productive early and midcareer scientists are facing having to close their labs. NIH and others 
have studied this problem, gathering data that suggest that over a certain level of funding to 
an individual investigator, there are diminishing returns in scientific output. Here I review 
these data and examine the issues that led NIH to propose and then reverse a cap on funding 
to individual investigators, the Grant Support Index. I consider other proposed solutions, and 
call on all in the field to examine whether the status quo is acceptable, and if not, urge them 
to propose and advocate for concrete alternatives.
It’s an exceptionally exciting time for basic biomedical science, as 
new tools drive exciting discoveries about the living world and offer 
new leads for treating disease. Some nations, like China, are em-
bracing these possibilities and dramatically increasing research 
investment (Kristiansen, 2014; Conte et al., 2017). The United States 
has been a world leader in biomedical research for decades be-
cause of the thoughtful way the National Institutes of Health (NIH) 
invested its portfolio, identifying talented young scientists from 
each generation and giving them the resources they needed to initi-
ate and maintain strong research programs. As the NIH budget in-
creased in the early 2000s, talented young scientists began labs at 
universities all across the nation, further expanding the biomedical 
enterprise beyond the traditional research hubs in the Northeast 
and on the West Coast. However, for the past decade or more the 
budget of the NIH has been losing ground in inflation-adjusted 
dollars (FASEB, 2017). This means that each dollar invested takes on 
additional importance to ensure the best outcome for science and 
society.
If you ask an investment advisor about the most sound and se-
cure way to invest your funds, the first answer will be simple: don’t 
put all of your eggs in one basket. A diverse investment portfolio 
reduces risk and increases the likelihood that you’ll include in your 
investments those that pay off best. The analogy to basic science is 
striking—the story of CRISPR, for example, reminds us how difficult 
it can be to predict which labs will contribute to fundamental new 
discoveries. A look at NIH’s investment portfolio suggests that it is 
now taking a different strategy. Its research dollars are invested in a 
strikingly uneven way—1% of scientists now get 11% of NIH fund-
ing, 10% get 40% (Collins, 2017; Lorsch, 2017; Figure 1).
All of us have seen the results at our own institutions and in the 
lives of colleagues in our fields. We have watched tightened grant 
funding threaten the careers of early and especially midcareer scien-
tists as they attempt to obtain or to renew investigator-initiated 
research grants in competition with the more senior leaders of their 
fields. Most of us know productive scientists who are faced with 
closing their labs. This is discouraging many of our best trainees 
from pursuing a research career. Simply put, it is a crisis (Alberts 
et al., 2015; FASEB, 2015; Kimble et al., 2015).
When we concentrate our investment dollars in fewer labs and 
projects, we risk failing to fund young investigators with great prom-
ise but without the long track record or extensive scientific staff or 
resources of their senior, well-funded colleagues. Two examples 
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from my own field illustrate this. In 1981 
Princeton hired a new assistant professor 
named Eric Wieschaus, who had just fin-
ished 4 years of collaborative work at EMBL 
in a team of four, carrying out genetic 
screens in the fruit fly. At around the same 
time, a young assistant professor at MIT, 
Robert Horvitz, and his small group of grad-
uate students were carrying out genetic 
screens in Caenorhabditis elegans. In our 
current system, it’s hard to know how their 
first NIH renewals would have fared if they 
were measured against well-funded labs 
with 25 or more postdocs and graduate 
students. But where would our fields be if 
they had not been able to continue the 
pathbreaking work that revolutionized de-
velopmental biology and led to the Nobel 
Prizes in Medicine and Physiology in 1995 
and 2002?
I am on the Council of the National Insti-
tute of General Medical Sciences (NIGMS) 
and have watched that institute take steps 
to try to expand the pool of talented and 
productive researchers who have access to 
research grants. By taking measures like 
closing down some “big science” pro-
grams, they have made slow but steady 
progress, with a resulting increase in R01 
success rates (Miklos and Lorsch, 2017). As 
part of this effort, NIGMS and the Office of 
the Director did an exceptionally thorough 
analysis of the distribution of research proj-
ect grants across the scientific spectrum, 
and how productivity and scientific impact 
scale with the amount of grant funding pos-
sessed by a principal investigator (PI). I saw 
these data at our May 2017 NIGMS Council 
meeting, when Jon Lorsch gave a very com-
pelling presentation. I would encourage ev-
eryone to review his slides (Lorsch, 2017).
While no data source is perfect, the 
analyses were performed across many sam-
ples, using many different metrics (Lorsch, 
2017). All the analyses tell a similar story. 
First, it is clear that impactful science costs 
money—a lab without grant funding can-
not have an impact. Second, the data sug-
gest that above a certain level of research 
project grant funding (R01 or equivalent), 
there are generally diminishing returns in 
scientific advances per unit dollar (Lauer 
et al., 2017; Lorsch, 2017; Figures 2 and 3). 
There has been much discussion of the sta-
tistical approaches used and what the curve 
really looks like at the far-right end, among 
the best-funded laboratories. With regard 
to this point, the NIH data fit well with that 
from several other published studies, all of 
which documented diminishing returns as 
funding levels increased (Fortin and Currie, 
2013; Xie, 2014; Conti and Liu, 2015; 
FIGURE 1: NIH research portfolio investment is skewed toward a small fraction of the 
investigators funded. Source: Presentation by NIGMS Director Jon Lorsch to NIGMS Council, 
May 26, 2017 (Lorsch, 2017). These data reflect all research dollars, but analyses restricted to 
research project grants are similar: 1% of scientists get 11% of funds, 10% of scientists get 37% 
of funds, and 20% of scientists get 52% of funds.
FIGURE 2: Evidence supporting diminishing returns at the upper end of the funding spectrum. 
Association of the annual weighted Relative Citation Ratio (RCR) among all papers linked to a 
scientist’s grants with annual Grant Support Index (GSI). Owing to skewed distributions, both 
RCR and GSI values are natural log-transformed; the numbers inside the axes represent the raw, 
nontransformed values. An annual GSI value of 7 corresponds to approximately one R01 grant, 
while annual GSI values of 14 and 21 correspond to two and three R01 grants. Note the 
decreasing slope of the regression curve as annual GSI increases. Source: Presentation by 
NIGMS Director Jon Lorsch to NIGMS Council, May 26, 2017 (Lorsch, 2017).
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Cook et al., 2015; Doyle et al., 2015; Lauer 
et al., 2015; Lorsch, 2015; Mongeon et al., 
2016). Third, as noted above, it is impossi-
ble to predict from where the most impor-
tant discoveries will emerge. The NIH anal-
ysis also addressed this aspect of research. 
Their data reveal that some of the most 
highly productive and highly cited scien-
tists had only a single grant, and relatively 
few of the most highly productive were in 
the top 5% of funded researchers (Lorsch, 
2017; Figure 4). This analysis strongly sug-
gests that the best approach is to bet on 
the highest number of qualified investiga-
tors. Finally, the data reveal that highly 
funded labs are no more likely to produce 
trainees who go on to grant-funded careers 
and thus help drive forward biomedical 
science (Lorsch, 2017)—as Jessica Polka 
has pointed out (Polka, 2017), the human 
capital produced by NIH dollars is another 
important output to consider.
Since this analysis was done, an indepen-
dent study (Katz and Matter, 2017) added 
further information about the impact of 
funding inequity, revealing that “funding in-
equality has been rising since 1985, with a 
small segment of investigators and institutes 
getting an increasing proportion of funds, 
and that investigators who start in the top 
funding ranks tend to stay there (which re-
sults in stasis, or lack of mobility).” In simple 
terms, the system, as it is currently set up, 
helps ensure that the rich get richer and the 
rest suffer the consequences.
Given these data, how can we broaden 
the NIH’s investment portfolio, helping en-
sure that we do not lose talented investiga-
tors from the system whose work might 
power the next important breakthroughs? 
Without substantial increases in the NIH 
budget, money must be reallocated to 
fund a larger number of investigators. A 
number of influential groups and people 
have looked at these and similar data over 
the past few years. An impressive report 
from the University of Wisconsin–Madison 
Workshop on “Rescuing the US Biomedical 
Research Enterprise: Strategies and Path-
ways Ahead” noted, “At the same time, 
NIH awards have shifted towards senior in-
vestigators at the expense of junior investi-
gators, and towards risk-averse projects, 
often with a translational focus. These shifts 
endanger the next generation of scientists, 
and they also endanger research in basic 
science, which has historically been the 
engine for groundbreaking discoveries. 
Our recommendations are designed to re-
verse these trends by redistributing funds 
to support both junior investigators and 
FIGURE 3: Evidence supporting diminishing returns at the upper end of the funding 
spectrum—non–log-transformed data. Source: Presentation by NIGMS Director Jon Lorsch 
to NIGMS Council, May 26, 2017 (Lorsch, 2017).
FIGURE 4: The vast majority of the most highly cited investigators did not exceed the GSI 
funding cap. Top 50 most highly cited investigators plotted vs. their level of NIH support. An 
annual GSI value of 7 corresponds to approximately one R01 grant, while annual GSI values of 
14 and 21 correspond to two and three R01 grants. More than half had the equivalent of two 
R01s or fewer while only seven of 50 exceeded the GSI cap (red line). Source: Presentation by 
NIGMS Director Jon Lorsch to NIGMS Council, May 26, 2017 (Lorsch, 2017).
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I was thus very disappointed to learn early in June 2017 that NIH 
abandoned the GSI before it even started (NIH Advisory Committee 
to the Director, 2017a). The tight timeline between its proposal and 
reversal meant that many scientists like me, who recognize the un-
derlying problem, did not rapidly and vocally support the underly-
ing idea, while at the same time pointing out needed tweaks. From 
the outside, it’s hard for me not to suspect that the feedback from a 
subset of very well-funded and powerful scientists threatened by 
this new approach tipped the balance. Importantly, the Advisory 
Committee (NIH Advisory Committee to the Director, 2017b) that 
made the decision to reverse the GSI did not represent the diversity 
of career stages affected by this critical decision. The reversal of the 
GSI policy sent a demoralizing message to many of us. I think if you 
ask your junior colleagues, whose voices were largely not taken into 
account in this discussion, you’ll find that the vast majority of them 
support some sort of funding limitations. My recent conversations 
with colleagues suggest a significant number of senior scientists 
also share these concerns. The almost 1500 people who have al-
ready signed a petition to NIH Director Francis Collins to reinstate a 
funding cap (Peifer, 2017) provide an indication of the breadth of 
this opinion.
As NIH considers solutions, it also has to consider a second ma-
jor issue, which, in my mind, underlies the reluctance of some of my 
senior colleagues to embrace the GSI: the seemingly unsustainable 
growth of soft-money or largely soft-money faculty positions at 
medical schools and research institutes. This played an important 
role in the reaction of many to the GSI proposal, some of whom 
struggle to obtain enough grant support to cover more than 70% of 
their salaries. While I, in a College of Arts and Sciences position, 
have 75% salary support, many in medical schools are under severe 
pressure in this regard (Berg, 2015). Jon Lorsch of NIGMS has fo-
cused attention on this issue in discussions with the Association of 
American Medical Colleges. It also needs to be considered in any 
effort to diversify the research portfolio, as any solution to the soft-
money problem will take time to implement.
My own goal is to see NIH develop a more diverse portfolio of 
NIH-funded research, opening up the field to a larger number of 
talented folks of all ages, while ensuring that taxpayer dollars are 
spent wisely. I think some mechanism that ensures that dollars are 
redistributed from the exceptionally well-funded few to support in-
vestigators who have no funding is essential. I continue to support 
the GSI, which provided a route forward. 
However, we could also consider other 
mechanisms to reach this goal. A dollar cap 
on funding similar to the NIGMS 750K pol-
icy (e.g., some have suggested $750K–1 
million/investigator; Rosbash, 2016; Wahls, 
2017) would also be a reasonable approach. 
Alternately, as Tom Pollard suggested in a 
recent post on the American Society for Cell 
Biology (ASCB) blog, we could consider 
some mechanism to limit lab size (Pollard, 
2017)—this would also be a way forward. 
All solutions need to recognize that differ-
ent sorts of science are more or less expen-
sive, but a concrete mechanism of diversify-
ing our research dollar investment to 
include more labs is, in my mind, essential.
NIH, in abandoning the GSI, sug-
gested a new initiative called the Next 
Generation Researcher Initiative (NGRI; 
NIH Office of Extramural Research, 2017). 
pioneering projects. That redistribution will be painful, especially 
for established senior investigators, but necessary to support the 
next generation and cutting edge research” (Kimble et al., 2015). 
Likewise, the FASEB Report “Sustaining Discovery in Biological 
and Medical Sciences: A Framework for Discussion” made a simi-
lar recommendation. “Limiting the amount of funding awarded to 
any individual scientist or laboratory would enable more people to 
be actively engaged in research. With more ‘hands at the bench,’ 
the number of ideas would increase, and this could expedite prog-
ress in many areas of science. Analyses produced by NIH as part of 
the call for suggestions on ‘Ways of Managing NIH Resources’ 
show that limiting a principal investigator’s total RPG support to 
$1 million would enable the funding of 2000 additional RPG 
awards at an average cost of $400,000″ (FASEB, 2015; numbers 
refer to direct costs). Finally, NIH asked community members to 
weigh in on this issue via an NIH Request for Information on “Op-
timizing Funding Policies and Other Strategies to Improve the Im-
pact and Sustainability of Biomedical Research.” Among the most 
common responses were suggestions to cap the number of grants 
or the amount of funding available to a given PI (Lorsch, 2017).
In response to these data, NIH proposed a bold solution—the 
Grant Support Index (GSI; Collins, 2017). The GSI proposed to cap 
the number of concurrent grants NIH would provide to a single in-
vestigator—roughly three Research Project Grants per lab head. NIH 
calculated that this cap would affect only 3% of all investigators, and 
the funds freed up could fund 900 new grants for PIs who did not 
have other grant funding (Lorsch, 2017). They also listened to com-
munity feedback and tweaked the formula to exempt training grants 
and to encourage collaboration (Lauer, 2017; Lorsch, 2017). This 
change was bold, addressing a key issue head on. Not too surpris-
ingly, there was pushback, the most strident and well-publicized of 
which seemed to be from a small number of very well-funded scien-
tists who seem unwilling to relinquish their hold on a disproportion-
ate amount of NIH funds. Some of their rhetoric was heated—one 
was quoted in the Boston Globe (Weisman, 2017) as saying, “If you 
have a sports team, you want Tom Brady on the field every time. You 
don’t want the second string or the third string.” For football fans (I’m 
not one, but so I was told), this comment was especially ironic as Tom 
Brady was the 199th overall pick in the sixth round of the NFL draft 
and warmed the bench his first year (Wikimedia, 2017). Undeterred, 
in May 2017 NIH seemed to be moving ahead with this program.
FIGURE 5: The fraction of NIH awardees who are midcareer investigators is declining. Source: 
Figure 4, Charette et al., 2016.
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While initiatives like this to support early-career scientists are 
welcome, they cannot have the same impact if they do not put a 
cap at the top. Without this, we may be simply rearranging the 
deck chairs on the Titanic. Two critical differences make the NGRI 
much less effective than the GSI. First, no source was designated 
for the funds needed. About 70% of all NIH-funded researchers 
have a single grant (Rockey, 2011; Lauer et al., 2017). Since the 
NGRI lacks a funding cap at the top and the NIH budget is a zero-
sum game, the NGRI may simply fund no-grant labs using dollars 
that would otherwise support a renewal to a lab with only a single 
grant. Thus the NGRI may not result in funding for a larger frac-
tion of productive labs. Furthermore, the NGRI is limited to those 
with 10 years or fewer of NIH grant funding. NIH analysis sug-
gests it is midcareer faculty who are struggling the most, as their 
fraction of the Research grant pie shrinks (Charette et al., 2016; 
Figure 5). New investigators currently benefit from some built-in 
advantages, at least at NIGMS, that help many of them get their 
first grant. It’s when they come in for a first, second, or third re-
newal that my colleagues are hitting the wall. The proposed 
NGRI excludes many of these midcareer scientists who are faced 
with shutting their labs.
I thus would urge all in the research community to consider 
these issues, asking whether maintaining the status quo is accept-
able, and if not, what solutions seem best. I hope these data stimu-
late a discussion among scientists at all career stages, including our 
trainees. Discussions are already underway at the ASCB and the 
Genetics Society of America, and the recent pieces published on 
the ASCB Post (ASCB Post Staff, 2017) end by soliciting views and 
feedback from all members. A committee commissioned by the 
National Academy of Sciences also asked for input on these issues 
(National Academy of Sciences, 2017). I personally hope that these 
discussions will lead the ASCB and other organizations like it to 
propose or support concrete proposals that will allow talented and 
productive junior investigators to start their labs and productive 
midcareer investigators to continue their work. This will require 
money, and since the NIH budget is likely not going to substan-
tially increase, like the GSI these proposals also must provide clear 
guidance about which programs or investigators will receive fewer 
dollars in order for this effort to be successful. There are also routes 
for individuals to take action. NIH is open to community feed-
back—contact NIH Director Francis Collins and make your views 
known (collinsf@mail.nih.gov, copying Deputy Director for Extra-
mural Research Michael.Lauer@nih.gov), and consider signing our 
petition (Peifer, 2017). Ask how NIH will address this issue and re-
quest concrete plans that include what programs will be reduced in 
order to broaden the NIH portfolio. Advocacy is also valuable, on 
this issue and others. Scientists of all ages can speak with their 
Congressional representatives about the value of basic and bio-
medical science and whether NIH should further diversify its 
investments.
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